International Journal of Rheumatology

Research Article

Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy

Table 1

Baseline characteristics of patients with rheumatoid arthritis.


		All	CR 24 W	Non-CR 24 W	value


Age (years)	Median [IQR]	62 [51–72]	64.0 [43.0–69.0]	62 [51.8–72.3]	0.392
Female (%) ()		83.1 (74)	81.0 (17)	83.8 (57)	0.746
BMI	Median [IQR]	21.3 [18.6–24.3]	21.0 [18.7–23.0]	21.5 [18.6–24.4]	0.800
Duration (years)	Median [IQR]	6.0 [2.0–16.0]	4.0 [2.0–9.0]	8.0 [2.0–18.3]	0.178
Stage I/II/III/IV		18/20/11/21	6/6/2/2	12/14/9/19	0.270
Biologic- and JAKinib-naïve status (%) ()		36.0 (32)	47.6 (10)	32.4 (22)	0.298
Biologic use history (%) ()		59.6 (53)	47.6 (10)	63.2 (43)	0.216
JAKinib use history (%) ()		9.0 (8)	4.8 (1)	10.3 (7)	0.675
Biologic and JAKinib use prior to JAKinib
TNFi (%) ()		39.3 (22)	63.6 (7)	32.6 (15)	0.397
IL-6Ri (%) ()		25.0 (14)	18.2 (2)	26.1 (12)
Abatacept (%) ()		21.4 (12)	9.1 (1)	23.9 (11)
Another JAKinib (%) ()		14.3 (8)	9.1 (1)	15.2 (7)
JAKinib
Tofacitinib (%) ()		37.1 (33)	47.6 (10)	33.8 (23)	0.305
Baricitinib (%) ()		62.9 (55)	52.4 (11)	66.2 (45)
MTX use (%) ()		68.5 (61)	76.2 (16)	66.2 (45)	0.435
MTX dose (mg/week)	Median [IQR]	10.0 [8.0–10.0]	10.0 [10.0–12.0]	8.0 [8.0–10.0]	0.0469
PSL use (%) ()		56.2 (50)	42.9 (9)	60.3 (41)	0.206
PSL dose (mg/day)	Median [IQR]	5.0 [3.0–7.5]	5.0 [5.0–7.5]	5.0 [3.0–7.5]	0.487
PSL discontinuation within 6 months (%) ()		14.0 (7)	22.2 (2)	12.2 (5)	0.595
SASP use (%)		32.6 (29)	28.6 (6)	33.8 (23)	0.792
IGU use (%)		9.0 (10)	4.8 (1)	13.2 (9)	0.441
BUC use (%)		9.0 (8)	4.8 (1)	10.3 (7)	0.675
TAC use (%)		14.6 (13)	4.8 (1)	17.6 (12)	0.386
ESR (mm/h)	Median [IQR]	35.0 [10.8–67.0]	33.5 [13.8–71.0]	35.0 [9.8–65.5]	0.487
CRP (mg/mL)	Median [IQR]	1.46 [0.24–3.12]	2.00 [0.82–2.60]	1.11 [0.15–3.13]	0.276
SDAI	Median [IQR]	18.9 [12.7–27.9]	19.0 [13.7–23.9]	18.5 [12.7–30.5]	0.850
eGFR-Crea (mL/min/1.73 m²)	Median [IQR]	84.5 [70.0–104.5]	101.5 [76.5–116.0]	82.0 [68.5–95.3]	0.0625

Abbreviations: CR: clinical remission; BMI: body mass index; IQR: interquartile range; SDAI: Simplified Disease Activity Index; eGFR-Crea: estimated glomerular filtration rate-creatinine; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; JAKi naïve: Janus kinase inhibitor naïve; JAKinib: Janus kinase inhibitor; MTX: methotrexate; PSL: prednisolone; SASP: salazosulfapyridine; IGU: iguratimod; BUC: bucillamine; TAC: tacrolimus; TNFi: tumour necrosing factor inhibitor; IL-6Ri: interleukin-6 receptor inhibitor.